Parkinson's disease
Conditions
Interventions
A single oral dose of 3 capsules of OP-2024 will be administered under any one meal condition (fasting, after meal or before meal) on Day 1 of each 3-day period in Periods 1, 2, and 3.
Sponsors
Taguchi Fumi
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Healthy Japanese male. 2) Age at the time of obtaining written informed consent is >= 18 to = 18.5 to < 25.0. 4) Written informed consent to participate in this trial can be obtained.
Exclusion criteria
Exclusion criteria: 1) History of allergy to investigational drug ingredients, drugs, or foods. 2) History of or undergoing treatment for any diseases of respiratory, circulatory, central nervous system, gastrointestinal, hepatic, renal, hematological, or endocrine disorders that affect pharmacokinetics. 3) Other protocol defined exclusion criteria could be applied.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety | — |
Contacts
Public ContactDepartment of Clinical Development
OHARA Pharmaceutical Co.,Ltd.
Outcome results
None listed